Clinical Trials Logo

Smoldering Multiple Myeloma clinical trials

View clinical trials related to Smoldering Multiple Myeloma.

Filter by:

NCT ID: NCT03850522 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma

Start date: February 18, 2019
Phase: Phase 2
Study type: Interventional

This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.

NCT ID: NCT03839459 Not yet recruiting - Clinical trials for Smoldering Multiple Myeloma

Denosumab for Smoldering Multiple Myeloma

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

NCT ID: NCT03815279 Not yet recruiting - Multiple Myeloma Clinical Trials

A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

iStopMM
Start date: April 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib.

NCT ID: NCT03717844 Recruiting - Multiple Myeloma Clinical Trials

Registry for Adults With Plasma Cell Disorders (PCD's)

Start date: February 9, 2018
Phase:
Study type: Observational [Patient Registry]

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).

NCT ID: NCT03657251 Not yet recruiting - Multiple Myeloma Clinical Trials

MMRF CureCloud Research Initiative

Start date: April 1, 2019
Phase:
Study type: Observational [Patient Registry]

The MMRF CureCloud Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 individuals from whom comprehensive molecular and immune analyses will be generated from blood specimens and the resulting data aggregated with the correlating clinical information. Blood will be collected from all participants after electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment. Through the consenting process, participants will also be authorizing linkage to their electronic medical records information.

NCT ID: NCT03631043 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Personalized Vaccine in Treating Participants With Smoldering Multiple Myeloma

Start date: December 21, 2018
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies the side effects of personalized vaccine in treating participants with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.

NCT ID: NCT03591614 Not yet recruiting - Myeloma Clinical Trials

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Start date: March 2019
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve Medical Center and then brought into contact with DKK1, a molecule that is present of myeloma cells but not to a significant amount on other cells except for the prostate and the placenta. It is an investigational (experimental) vaccine that based on studies in the laboratory and in mice is expected to work by presentation of DKK1 to anticancer immune cells via dendritic cells leading to an immune attack on myeloma cells. It is experimental because it is not approved by the Food and Drug Administration (FDA).

NCT ID: NCT03301220 Recruiting - Clinical trials for Smoldering Multiple Myeloma

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Start date: November 7, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).

NCT ID: NCT03289299 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

ASCENT
Start date: May 25, 2018
Phase: Phase 2
Study type: Interventional

This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.

NCT ID: NCT03236428 Recruiting - Clinical trials for Smoldering Multiple Myeloma

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Start date: November 24, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab